Immunis, Inc. is an Irvine, California clinical-stage biotechnology company developing secretome-based 'multi-active' biologics for age-related disease. Its proprietary process isolates clinical-grade secreted cellular factors from stem cells that modulate immune function and act on multiple signaling pathways at once. The company's lead investigational product, IMM01-STEM, is an off-the-shelf biologic targeting age-related muscle loss and metabolic decline. It has completed a Phase 1/2a trial in sarcopenic patients with knee osteoarthritis and is running a Phase 2 placebo-controlled study in adults over 50 with sarcopenic obesity.